Unither Pharmaceuticals: Difference between revisions
(Created page with "== History == Established in 1993 through the acquisition of a Sanofi plant, the company's initial focus was on producing sterile single-dose polyethylene products like saline, asthma treatments, and eye drops. Making use of Blow Fill Seal (BFS) technology in 1995 allowed the creation of sterile doses in a single manufacturing step. By 1997, the company had expanded its presence to global markets, exporting to Europe and building expertise for international customers. Un...") |
|||
| Line 1: | Line 1: | ||
Unither Pharmaceuticals is a prominent contract pharmaceutical product manufacturing service provider catering to the healthcare and generic drug sector. The company's core expertise lies in producing and packaging sterile unit doses, non-sterile liquids, solid, and semi-solid medications. It leverages advanced technologies such as blow-fill-seal (BFS) and liquid stick-packs to deliver these products. Additionally, Unither offers regulatory insight, galenic development, and analytical services, facilitating clients' outsourcing of their manufacturing needs. | |||
Founded in 1993 in Amiens, France, Unither Pharmaceuticals specializes in developing and manufacturing liquid single-dose forms, including eye drops, saline solutions, asthma medications in BFS unit doses, as well as over-the-counter (OTC) and prescription (Rx) formulations in stick packs. With a workforce exceeding 2000 individuals across 8 manufacturing facilities spanning France, the United States, Brazil, and China, Unither Pharmaceuticals achieved notable success, recording sales of €371 million in 2022. | |||
== History == | == History == | ||
Established in 1993 through the acquisition of a Sanofi plant, the company's initial focus was on producing sterile single-dose polyethylene products like saline, asthma treatments, and eye drops. Making use of Blow Fill Seal (BFS) technology in 1995 allowed the creation of sterile doses in a single manufacturing step. By 1997, the company had expanded its presence to global markets, exporting to Europe and building expertise for international customers. Unither's growth continued with the acquisition of a second sterile single-dose unit manufacturing plant in Coutances, France, in 2002. In 2005, they furthered their expansion by acquiring Créapharm, specializing in effervescent tablets. The launch of Unistick® stick-packs in 2006 marked a significant advancement in providing single-dose stick solutions. Over the years, Unither continued to expand its technologies, facilities, and international reach, including the acquisition of the Colomiers site in 2009, the launch of Uniflash® in 2010, the opening of a plant in Butantã, São Paulo, Brazil in 2011, and the acquisition of various plants, including the Novartis plant in 2022 | Established in 1993 through the acquisition of a Sanofi plant, the company's initial focus was on producing sterile single-dose polyethylene products like saline, asthma treatments, and eye drops. Making use of Blow Fill Seal (BFS) technology in 1995 allowed the creation of sterile doses in a single manufacturing step. By 1997, the company had expanded its presence to global markets, exporting to Europe and building expertise for international customers. Unither's growth continued with the acquisition of a second sterile single-dose unit manufacturing plant in Coutances, France, in 2002. In 2005, they furthered their expansion by acquiring Créapharm, specializing in effervescent tablets. The launch of Unistick® stick-packs in 2006 marked a significant advancement in providing single-dose stick solutions. Over the years, Unither continued to expand its technologies, facilities, and international reach, including the acquisition of the Colomiers site in 2009, the launch of Uniflash® in 2010, the opening of a plant in Butantã, São Paulo, Brazil in 2011, and the acquisition of various plants, including the Novartis plant in 2022 | ||
Revision as of 13:53, 24 August 2023
Unither Pharmaceuticals is a prominent contract pharmaceutical product manufacturing service provider catering to the healthcare and generic drug sector. The company's core expertise lies in producing and packaging sterile unit doses, non-sterile liquids, solid, and semi-solid medications. It leverages advanced technologies such as blow-fill-seal (BFS) and liquid stick-packs to deliver these products. Additionally, Unither offers regulatory insight, galenic development, and analytical services, facilitating clients' outsourcing of their manufacturing needs.
Founded in 1993 in Amiens, France, Unither Pharmaceuticals specializes in developing and manufacturing liquid single-dose forms, including eye drops, saline solutions, asthma medications in BFS unit doses, as well as over-the-counter (OTC) and prescription (Rx) formulations in stick packs. With a workforce exceeding 2000 individuals across 8 manufacturing facilities spanning France, the United States, Brazil, and China, Unither Pharmaceuticals achieved notable success, recording sales of €371 million in 2022.
History
Established in 1993 through the acquisition of a Sanofi plant, the company's initial focus was on producing sterile single-dose polyethylene products like saline, asthma treatments, and eye drops. Making use of Blow Fill Seal (BFS) technology in 1995 allowed the creation of sterile doses in a single manufacturing step. By 1997, the company had expanded its presence to global markets, exporting to Europe and building expertise for international customers. Unither's growth continued with the acquisition of a second sterile single-dose unit manufacturing plant in Coutances, France, in 2002. In 2005, they furthered their expansion by acquiring Créapharm, specializing in effervescent tablets. The launch of Unistick® stick-packs in 2006 marked a significant advancement in providing single-dose stick solutions. Over the years, Unither continued to expand its technologies, facilities, and international reach, including the acquisition of the Colomiers site in 2009, the launch of Uniflash® in 2010, the opening of a plant in Butantã, São Paulo, Brazil in 2011, and the acquisition of various plants, including the Novartis plant in 2022